Essential Thrombocythemia
Mostrando 1-12 de 21 artigos, teses e dissertações.
-
1. Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese
ABSTRACT Introduction: Constitutional symptoms and thrombohemorrhagic events are common in patients with myeloproliferative neoplasms (MPNs). Hence, the treatment’s primary goal is to control symptoms and improve the quality of life (QoL). In order to assess response to therapy, symptom burden, and QoL among patients with MPN, the “Myeloproliferative Ne
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
2. Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms
ABSTRACT Background: The classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) are Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). In developing countries, there are few reports that truly reveal the clinical setting of these patients. Therefore, we aimed to characterize a single center MPN population with a
Hematol., Transfus. Cell Ther.. Publicado em: 2020-09
-
3. Essential thrombocythemia - a predisponent factor for stroke
SUMMARY The essential thrombocythemia is one of the seven described forms of myeloproliferative neoplasms. It is characterized by megakaryocytic hyperplasia with consequent thrombocytosis maintained in the peripheral blood, favoring the occurrence of thrombo-hemorrhagic phenomena. We present the case of an 81-year-old woman with a history of ischemic stroke
Rev. Assoc. Med. Bras.. Publicado em: 22/07/2019
-
4. Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
ABSTRACT Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms. Methods: This study examined the plasma cytokine profiles of patients with essential thrombocythemia, primary myelofibrosis,
Hematol., Transfus. Cell Ther.. Publicado em: 2018-06
-
5. Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
ABSTRACTMyeloproliferative neoplasms are caused by a clonal proliferation of a hematopoietic progenitor. First described in 1951 as 'Myeloproliferative Diseases' and reevaluated by the World Health Organization classification system in 2011, myeloproliferative neoplasms include polycythemia vera, essential thrombocythemia and primary myelofibrosis in a subgr
Rev. Bras. Hematol. Hemoter.. Publicado em: 2015-10
-
6. Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factor
Objective: The aim of this work was to demonstrate a possible relationship between anti-latency-associated peptide human latent transforming growth factor beta 1 (latent TGF-β1) expression in megakaryocytes and microvascular density in bone marrow biopsies from patients with essential thrombocythemia and primary myelofibrosis. Methods: Microvascular dens
Rev. Bras. Hematol. Hemoter.. Publicado em: 2014-10
-
7. Essential thrombocythemia: a rare disease in childhood
Essential thrombocythemia is an acquired myeloproliferative disorder characterized by the proliferation of megakaryocytes in bone marrow, leading to a persistent increase in the number of circulating platelets and thus increasing the risk for thrombotic and hemorrhagic events. The disease features leukocytosis, splenomegaly, vascular occlusive events, hemorr
Rev. Bras. Hematol. Hemoter.. Publicado em: 2013
-
8. Alterações da expressão de apoptomirs, de genes e proteínas pró- e anti-apoptóticos em Mielofibrose e Trombocitemia Essencial / Deregulated expression of apoptomirs and apoptosis-related genes and proteins in Primary Myelofibrosis and Essential Thrombocythemia
As Neoplasias Mieloproliferativas Crônicas (NMPC) Trombocitemia Essencial (TE), Mielofibrose (MF) - são desordens hematopoéticas resultantes da expansão clonal da célula tronco hematopoética alterada. Essas doenças caracterizam-se pela independência dos progenitores hematopoéticos aos estímulos dos fatores de crescimento e citocinas e pela prolifer
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 11/10/2011
-
9. Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVE: The aim of this study was to detect the following mutations: JAK2 V617F, JAK2 exon 12 and MPL W515K/L, besides chromosomal abnormalities. Furthermore, molecular and cytogenetic alterations
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2011-12
-
10. The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2011-12
-
11. Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms
Chronic myeloproliferative neoplasms arise from clonal proliferation of hematopoietic stem cells. According to the World Health Organization myeloproliferative neoplasms are classified as: chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic neutrophilic leukemia, chronic eosinophilic leukemia, hypereosin
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2011
-
12. Analysis of the -398C/T polymorphism in the perforin gene in oncohematological patients
BACKGROUND: Recently, single nucleotide polymorphisms (SNPs) were identified in the promoter region of the perforin gene (PRF1) and it was found that the -398T mutant allele is correlated with lower amounts of protein in circulating CD8+ cytotoxic T lymphocytes. OBJECTIVE: The aim of this study was to investigate the presence of the -398C/T polymorphism in t
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2011